TOKYO & BOSTON — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. [Read more…]
FREE organoid and organ-on-chip TRAINING and TICKETS at WORD+2025!
We are excited to announce these latest organoid and organ-on-a-chip partnerships for training and publishing.
WORC.Community, the founders of WORD+2025, QMUL Centre for Predictive in vitro Models and the University of Bern are excited to announce a new Organoid and Organ-on-a-chip training partnership on day three of WORD+2025. The training is a series of interactive lectures in the main auditorium. You’ll learn about the latest techniques and key methods employed at both universities. In addition, there will also be demonstrations from key technologies used in their workflows. [Read more…]
Elevai Labs Releases Preliminary Positive Research on the Potential of Exosome Technology for Skin Health
Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai’s hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin’s extracellular matrix (“ECM”).
Data implies ELEVAI exosomes™ may be a source for proteins that typically decrease with age, and can be important components that prevent skin thinning, loss of elasticity and wrinkle formation.
Proudly Supporting Great Science and Women in STEM
WORD+ 2025 is pleased to introduce its conference chairs and speakers.
FYI: In February 2025, 60% of session chairs and 54% of speakers will be leading scientists who are female. [Read more…]
Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions
MONT-SAINT-GUIBERT, Belgium — Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its first-of-its kind facility dedicated to manufacturing therapies based on induced pluripotent stem cells (iPSCs). This achievement signifies Cellistic’s quality and regulatory readiness, which is now certified by the Belgian Federal Agency for Medicines and Health Products (FAMHP), operating under European Medicines Agency (EMA) guidelines. [Read more…]
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 117
- Next Page »